Tweet
Source: http://www.independentweekly.com.au/...l/1553628.aspx
Volunteers sought for swine flu vaccine trial
29/06/2009 12:47:00 PM
Volunteers are being sought to take part in the clinical trial of a new vaccine against swine flu being conducted by biopharmaceutical company CSL Limited and the Royal Adelaide Hospital.
CSL says healthy adults aged between 18 and 64 years are needed for the trial, which will involve receiving two injections of the vaccine, three weeks apart.
?We understand flu vaccines very well from our long experience with yearly seasonal strains, as well as research into novel flu vaccines,? global director of clinical development at CSL, Dr Russell Basser, said today.
?We appreciate that new influenza strains like the ?swine flu? can surprise us with properties that mean they might require higher dosing and two injections rather than one to provoke the desired level of immune response in humans.
?CSL will be addressing these questions in the trial to ensure we know the optimum way for the vaccine to be given to protect against this strain of flu.?
The trial is expected to begin in mid-July, and volunteers will need to submit to blood tests to check that they are generating an appropriate immune response to the virus. CSL said they must be available to meet four appointments in Adelaide over a six-month period.
Dr Basser said the trial was being conducted with view to fulfilling a commitment to the Australian Department of Health and Ageing to supply up to 10 million people with a vaccine against Novel H1N1 ?swine? influenza.
Volunteers sought for swine flu vaccine trial
29/06/2009 12:47:00 PM
Volunteers are being sought to take part in the clinical trial of a new vaccine against swine flu being conducted by biopharmaceutical company CSL Limited and the Royal Adelaide Hospital.
CSL says healthy adults aged between 18 and 64 years are needed for the trial, which will involve receiving two injections of the vaccine, three weeks apart.
?We understand flu vaccines very well from our long experience with yearly seasonal strains, as well as research into novel flu vaccines,? global director of clinical development at CSL, Dr Russell Basser, said today.
?We appreciate that new influenza strains like the ?swine flu? can surprise us with properties that mean they might require higher dosing and two injections rather than one to provoke the desired level of immune response in humans.
?CSL will be addressing these questions in the trial to ensure we know the optimum way for the vaccine to be given to protect against this strain of flu.?
The trial is expected to begin in mid-July, and volunteers will need to submit to blood tests to check that they are generating an appropriate immune response to the virus. CSL said they must be available to meet four appointments in Adelaide over a six-month period.
Dr Basser said the trial was being conducted with view to fulfilling a commitment to the Australian Department of Health and Ageing to supply up to 10 million people with a vaccine against Novel H1N1 ?swine? influenza.
Comment